



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Panitumumab

Cat. No.:	HY-P99041
CAS No.:	339177-26-3
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer<sup>[1][2][4]</sup>.</p>								
<b>In Vitro</b>	<p>Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells<sup>[3]</sup>.</p> <p>?Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells<sup>[4]</sup>.</p> <p>?Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[3]</sup></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells</td> </tr> <tr> <td>Concentration:</td> <td>2, 20, 200, 2000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>3 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited ligand-induced autophosphorylation of EGFR.</td> </tr> </table>	Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells	Concentration:	2, 20, 200, 2000 nM	Incubation Time:	3 h	Result:	Inhibited ligand-induced autophosphorylation of EGFR.
Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells								
Concentration:	2, 20, 200, 2000 nM								
Incubation Time:	3 h								
Result:	Inhibited ligand-induced autophosphorylation of EGFR.								
<b>In Vivo</b>	<p>Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P &lt; 0.0003)<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>NCI-H1975 and NCI-H1650 xenografts<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>25, 100, or 500 μg/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.), twice a week</td> </tr> <tr> <td>Result:</td> <td>Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.</td> </tr> </table>	Animal Model:	NCI-H1975 and NCI-H1650 xenografts <sup>[3]</sup>	Dosage:	25, 100, or 500 μg/mouse	Administration:	Intraperitoneal injection (i.p.), twice a week	Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
Animal Model:	NCI-H1975 and NCI-H1650 xenografts <sup>[3]</sup>								
Dosage:	25, 100, or 500 μg/mouse								
Administration:	Intraperitoneal injection (i.p.), twice a week								
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.								

---

## CUSTOMER VALIDATION

- Sci Rep. 2022 Jul 7;12(1):11561.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Yu Jo Chua, et al. Panitumumab. *Drugs Today (Barc)*. 2006 Nov;42(11):711-9.
- [2]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. *Expert Opin Drug Saf*. 2014 Jun;13(6):843-51.
- [3]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. *Mol Cancer Ther* (2009) 8 (6): 1536–1546.
- [4]. Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. *Anticancer Res*. 2009 Dec;29(12):5077-82.
- [5]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. *Anticancer Res*. 2009 Dec;29(12):5077-82. PMID: 20044619...
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA